H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Check-Cap (CHEK – Research Report) today and set a price target of $3.00. The company’s shares opened today at $0.32.
Chen covers the Healthcare sector, focusing on stocks such as Veru, Prophase Labs, and Belite Bio, Inc. ADR. According to TipRanks, Chen has an average return of -14.1% and a 30.60% success rate on recommended stocks.
Check-Cap has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.
See today’s best-performing stocks on TipRanks >>
Based on Check-Cap’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5.83 million. In comparison, last year the company had a GAAP net loss of $3.57 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in developing gastrointestinal imaging devices. It develops capsule-based system that utilizes low-dose X-rays to detect polyps, masses and colorectal cancer screening. The company was founded by Yoav Kimchy in 2005 and is headquartered in Isfiya, Israel.
Read More on CHEK:
- Fancamp Exploration Ltd. Acquires Securities of KWG Resources Inc.
- Vita Coco Partners with Beautiful Destinations to Celebrate Coconut Farming Communities on World Coconut Day
- Healthequity (HQY) Receives a Buy from Barrington
- CCC Intelligent Solutions Holdings (CCCS) Receives a New Rating from a Top Analyst
- INTERNATIONAL GAME TECHNOLOGY PLC ANNOUNCES CAPPED TENDER OFFER WITH RESPECT TO ITS 6.500% SENIOR SECURED NOTES DUE 2025 AND 3.500% SENIOR SECURED NOTES DUE 2024
